Emsam Anti-Depressant Patch NDA Resubmission On Track For 2003 – Mylan
Mylan Laboratories hopes for FDA approval of the transdermal selegiline product Emsam by mid 2004, Mylan Vice Chairman Robert Coury said during a July 25 conference call
You may also be interested in...
Watson Pharmaceuticals expects the overactive bladder patch Oxytrol to be cleared by FDA in the first quarter of 2003, following receipt of a "not approvable" letter March 26
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials